Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
Our primary objective is to further characterize the mechanism by which alpha-1PI regulates CD4 counts. HIV-1 infected patients will be initiated on PROLASTIN®-C (Alpha-1 Proteinase Inhibitor \[Human\], Grifols Biotherapeutics Inc.) or placebo. Uninfected volunteers will be untreated and will be monitored for comparison.
Epistemonikos ID: d469b8d37813ee0289822a174beb0a084f119dca
First added on: Mar 23, 2020